The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...
The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...
Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd brought ...
NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.
AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and HER2 ...
Astrazeneca shares rose nearly 1% following unexpectedly positive interim results from a Phase III trial of its breast cancer drug Camizestrant. The study revealed that patients with hormone ...
New York State Common Retirement Fund grew its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% during the 4th ...
Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
"The goal is to expand treatment options for HER2-mutant NSCLC, which is currently a challenging and prognostically ...
As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.